BEIJING: An inactivated Covid-19 vaccine candidate developed by China is safe and generates an immune response, according to data from clinical trials published in The Journal of the American Medical Association this week.
The research paper provided an interim analysis of the phase-1 and phase-2 clinical trials of an inactivated Covid-19 vaccine developed by the Wuhan Institute of Biological Products under the China National Biotec Group (CNBG), affiliated to Sinopharm as well as the Wuhan Institute of Virology under the Chinese Academy of Sciences.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
